Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912–4

Rapid Response ◽

Letter To The Editor ◽

Cell Death Protein ◽

Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912–4

European Urology ◽

10.1016/j.eururo.2016.02.048 ◽

2016 ◽

Vol 70 (3) ◽

pp. e75-e76

Author(s):

Tim N. Beck ◽

Erica A. Golemis ◽

Daniel M. Geynisman

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Rapid Response ◽

Letter To The Editor ◽

Cell Death Protein ◽

Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features

European Urology ◽

10.1016/j.eururo.2015.07.008 ◽

2015 ◽

Vol 68 (5) ◽

pp. 912-914 ◽

Cited By ~ 41

Author(s):

Daniel M. Geynisman

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Rapid Response ◽

Cell Death Protein ◽

Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912–4

European Urology ◽

10.1016/j.eururo.2016.06.039 ◽

2017 ◽

Vol 71 (1) ◽

pp. e27-e28

Author(s):

M. Francesca Monn ◽

Liang Cheng ◽

Marina Scarpelli ◽

Antonio Lopez-Beltran ◽

Rodolfo Montironi

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Rapid Response ◽

Cell Death Protein ◽

Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912–4

European Urology ◽

10.1016/j.eururo.2016.02.049 ◽

2016 ◽

Vol 70 (3) ◽

pp. e72-e74 ◽

Cited By ~ 4

Author(s):

Francesco Piva ◽

Matteo Santoni ◽

Marina Scarpelli ◽

Alberto Briganti ◽

Antonio Lopez-Beltran ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Rapid Response ◽

Cell Death Protein ◽

Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma

OncoImmunology ◽

10.1080/2162402x.2017.1413519 ◽

2018 ◽

Vol 7 (4) ◽

pp. e1413519 ◽

Cited By ~ 10

Author(s):

Kyu Seo Kim ◽

Rishi R. Sekar ◽

Dattatraya Patil ◽

Michelle A. Dimarco ◽

Haydn T. Kissick ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Prognostic Biomarker ◽

Cell Renal Cell Carcinoma ◽

Cell Death Protein

Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma

Translational Andrology and Urology ◽

10.21037/tau-21-406 ◽

2021 ◽

Vol 10 (5) ◽

pp. 2091-2102

Author(s):

Zhiling Zhang ◽

Longbin Xiong ◽

Zeshen Wu ◽

Huiming Liu ◽

Kang Ning ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Dendritic Cell ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Killer Cells ◽

Cell Death Protein

Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis

Cancer Treatment Reviews ◽

10.1016/j.ctrv.2021.102242 ◽

2021 ◽

pp. 102242

Author(s):

Keiichiro Mori ◽

Benjamin Pradere ◽

Fahad Quhal ◽

Satoshi Katayama ◽

Hadi Mostafaei ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Programmed Cell Death 1

Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155221989424 ◽

2021 ◽

Vol 27 (2) ◽

pp. 266-267

Author(s):

Nour Khalil ◽

Julien Sarkis ◽

Georges Abi Tayeh

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Programmed Cell Death 1

Programmed cell death ligand 1 and tumor‐infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation

Cancer ◽

10.1002/cncr.30937 ◽

2017 ◽

Vol 123 (24) ◽

pp. 4823-4831 ◽

Cited By ~ 29

Author(s):

Fumi Kawakami ◽

Kanishka Sircar ◽

Jaime Rodriguez‐Canales ◽

Bryan M. Fellman ◽

Diana L. Urbauer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Cell Carcinoma ◽

Renal Cell ◽

Tumor Infiltrating Lymphocyte

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

IJU Case Reports ◽

10.1002/iju5.12173 ◽

2020 ◽

Vol 3 (5) ◽

pp. 176-179 ◽

Cited By ~ 1

Author(s):

Yoko Maegawa ◽

Taigo Kato ◽

Shinichiro Fukuhara ◽

Hiroshi Kiuchi ◽

Ryoichi Imamura ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Death ◽

Programmed Cell Death ◽

Adverse Events ◽

Cell Carcinoma ◽

Renal Cell ◽

Experienced Patient ◽

Programmed Cell Death 1